Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [ 212

#CATX Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026 VMT-α-NET study on track to achieve nearly one year of follow-up in all 46

#CATX Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

www.stocktitan.net/news/CATX/perspective-th...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CATX, #VIAV, #CCL, #TROW, #FCX

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CATX, #PYPL, #CRWD, #PAAS, #BULL

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CATX 6.1x
2. #VIAV 3.6x
3. #CCL 2.6x
4. #TROW 2.5x
5. #CMCSA 2.2x

#OptionFlow #OptionsTrading #Trading

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium Updated interim results with an additional ~13 weeks of follow-up since the prior update [ 212 Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both

#CATX Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated data for its [212Pb]VMT-α-NET program were accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026.The accepted poster, presented by Thorvardur Halfdanarson from Mayo Clinic Comprehensive Cancer Center, covers safety and preliminary efficacy results in advanced SSTR2-expressing neuroendocrine tumors. The poster is Abstract No. 635 in the session "Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract" and will be shown on January 9, 2026 at two times: 11:30 am–1:00 pm PT and 5:00–6:00 pm PT. ASCO-GI will release full regular-abstract details on January 5, 2026.

#CATX Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

www.stocktitan.net/news/CATX/perspective-th...

#CATX Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results Perspective Therapeutics (NYSE AMERICAN: CATX) will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes.The company said the related press release will be published on its newsroom at https://perspectivetherapeutics.com/newsroom/press-releases.

#CATX Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 Perspective Therapeutics (NYSE: CATX) reported updated interim Phase 1/2a results for [212Pb]VMT-α-NET with a data cut-off of Sept 12, 2025, presented at ESMO 2025.Key findings: 55 patients received at least one dose; no dose limiting toxicities or treatment-related discontinuations; Objective Response Rate 44% (7/16) in Cohort 2 patients with SSTR2 expression in all tumors at a median follow-up of 41 weeks; 14 of 16 such patients (87.5%) were progression-free and on study. Additional interim efficacy data for 23 Cohort 2 and 8 Cohort 3 patients are expected in 2026. Preliminary cash was $174.1M as of Sept 30, 2025, projected to fund operations into late 2026. A webcasted conference call was held on Oct 20, 2025 at 8:30 AM ET.

#CATX Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

www.stocktitan.net/news/CATX/perspective-th...

Cancer Trial Milestone: Perspective's PSV359 Advances to Higher Dose for FAP-α Positive Tumor Treatment Biotech firm initiates second cohort with 5.0 mCi dose of [212Pb]PSV359 for FAP-α positive solid tumors. Safety committee approves dose increase following initial 2.5 mCi cohort evaluation.

#CATX Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

www.stocktitan.net/news/CATX/perspective-th...

Ein Bild – viele Displays

#CatX #DigitalSignage #DigitalSignageExtender @digitalsignage.de #Extender #HDMIKVM #Signalverteiler

netzpalaver.de/2025/...

Novel Alpha Therapy [212Pb]VMT01: Perspective Therapeutics Escalates Dose in Advanced Melanoma Trial Biotech firm advances Phase 1/2a melanoma study with 3.0 mCi [212Pb]VMT01 dose combined with nivolumab. Safety committee approves dose increase following positive early data.

#CATX Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

www.stocktitan.net/news/CATX/perspective-th...

🦁 Batalha do safari de setembro 🐯

🐈‍⬛ É hora da Batalha Felina! Vote no seu token meme com tema de cão favorito. Dez vencedores sortudos dividirão o prêmio semanal de 100 #USDT.

🐶 Tokens: #CATI, #CATS, #POPCAT, #MEW, #TOSHI, #CATX

👉 Saiba mais: t.me/KuCoinPortug...

Boa sorte! 🍀

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results Perspective Therapeutics (NYSE:CATX) reported Q2 2025 results and provided clinical updates on its radiopharmaceutical pipeline. The company's lead candidate [212Pb]VMT-α-NET showed promising results in neuroendocrine tumors, with 4 out of 7 patients in Cohort 2 experiencing objective responses and 7 of 9 patients remaining progression-free after one year. The FDA approved advancement to Cohort 3 (6.0 mCi) in June 2025.The company reported $192M in cash as of June 30, 2025, expected to fund operations into late 2026. Q2 2025 financial results showed a net loss of $21.5M ($0.29 per share), compared to $11.7M in Q2 2024. R&D expenses increased 79% to $16.6M, while G&A expenses rose 40% to $7.7M.Clinical progress continues across three programs: VMT-α-NET, VMT01 for melanoma, and PSV359 for FAP-α expressing tumors. Updated trial results will be presented at ESMO Congress 2025 in October.

#CATX Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

www.stocktitan.net/news/CATX/perspective-th...

Major Breakthrough: Phase 2 NET Cancer Treatment Shows Mature Safety Data in 44 Patients, ESMO Preview Latest VMT-α-NET therapy data reveals mature safety outcomes and preliminary efficacy in neuroendocrine tumor patients. Key findings to be presented at ESMO 2025. Get insights.

#CATX Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

www.stocktitan.net/news/CATX/perspective-th...

Cancer Treatment Pioneer Perspective Therapeutics Announces Q2 2025 Earnings Date: Key Updates Coming Radiopharmaceutical innovator Perspective Therapeutics schedules Q2 earnings and business update. Learn about latest cancer treatment developments. Get insights.

#CATX Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting Perspective Therapeutics (NYSE: CATX) presented two key studies at SNMMI 2025 Annual Meeting in New Orleans. The first presentation focused on dosimetry findings for [212Pb]VMT-α-NET in treating neuroendocrine tumors, demonstrating feasibility and well-tolerated safety profile in Phase 1/2a trials. The study suggests this dosimetric approach could be valuable for developing 212Pb-based therapies. The second presentation introduced [68Ga]PSV377, a novel PET imaging agent for FAP-α expressing tumors, showing promising results in preclinical studies and first-in-human imaging, with superior tumor uptake compared to 18F-FDG in metastatic colorectal cancer patients.

#CATX Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial Perspective Therapeutics (CATX) has advanced its Phase 1/2a clinical trial for [212Pb]VMT-α-NET by opening Cohort 3 after FDA alignment. The trial targets patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who haven't received prior radiopharmaceutical therapies. Cohort 3 will administer higher doses (6 mCi) - a 20% increase from Cohort 2. Patients weighing over 60kg will receive four fixed doses every eight weeks, while those under 60kg will receive 100μCi/kg. The company will evaluate dose-limiting toxicities in up to eight patients within 42 days of first treatment to determine maximum tolerated or feasible dose. Initial results from Cohort 2 showed promising anti-tumor activity with primarily low-grade adverse events. The company plans to present additional clinical updates, including safety follow-up and anti-tumor activities, at scientific conferences in the second half of 2025.

#CATX Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

www.stocktitan.net/news/CATX/perspective-th...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jun 3rd - #CIFR #RSLS #VLRS #TNGX #SEDG #PSIX #NVTS #MCTR #LTBR #LEU #KULR #KIDZ #GRYP #DNN #CGEN #CATX #BTCS #ASPI #APLD #AI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Just In: ( NYSE: #CATX ) Healthcare Stock Soars On RBC Capital Outlook

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting Perspective Therapeutics (CATX) presented updated interim data from its Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors at ASCO 2025. The trial showed promising results with 42 patients treated across two cohorts (2.5 mCi and 5.0 mCi). Key findings include: favorable safety profile with no dose-limiting toxicities or treatment discontinuations, 4 out of 7 patients in Cohort 2 achieving objective responses (3 confirmed), and 7 out of 9 patients remaining progression-free after one year. The drug demonstrated durable anti-tumor activity at Cohort 2's dose level, with one patient maintaining response for over 10 months. The company plans to continue dose-finding studies pending FDA consultation and will present additional safety and efficacy data later in 2025.

#CATX Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

www.stocktitan.net/news/CATX/perspective-th...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FUBO, #BTI, #CATX, #SXC, #LH

#OptionFlow #OptionsTrading #Trading

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results Perspective Therapeutics (NYSE: CATX) reported key developments for Q1 2025 and provided updates on their clinical pipeline. The company is advancing three clinical-stage radiopharmaceutical therapies: 1. VMT-α-NET: 40 patients enrolled through April 2025 in Phase 1/2a trial for neuroendocrine tumors, with data accepted for ASCO presentation. 2. VMT01: First patients treated with new monotherapy dose and in combination with nivolumab for melanoma treatment. 3. PSV359: Achieved first-in-human dosing for FAP-α targeting therapy for solid tumors. The company is expanding U.S. manufacturing capabilities with two operational facilities and three additional sites under development. Financial position remains strong with $212M in cash and equivalents as of March 31, 2025, expected to fund operations into late 2026. Recent patent allowances strengthen their intellectual property portfolio through 2041-2044.

#CATX Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

www.stocktitan.net/news/CATX/perspective-th...

Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial Novel targeted alpha therapy advances with higher dose testing. Potential breakthrough for melanoma patients with brain metastases. See latest trial developments.

#CATX Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

www.stocktitan.net/news/CATX/perspective-th...

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results Perspective Therapeutics (NYSE: CATX) provided its full year 2024 results and business highlights, reporting strong progress across its clinical programs. The company maintains a robust cash position of $227 million as of December 31, 2024, expected to fund operations into late 2026.Key developments include:VMT-α-NET trial enrolled 30 patients through February 2025 in Cohort 2, with promising early safety and efficacy dataFirst-in-human combination dosing of VMT01 with nivolumab achieved in March 2025IND clearance received for PSV359 targeting FAP-α, with first patient dosing expected mid-2025Expansion of manufacturing capabilities through facility acquisitions in Houston, Chicago, and Los Angeles for $20.7 million€49.0 million equipment and services agreement with Comecer SpA for production facilities

#CATX Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

www.stocktitan.net/news/CATX/perspective-th...

Breakthrough Melanoma Treatment: New Alpha Therapy Combined With Opdivo Shows Promise Perspective Therapeutics advances melanoma treatment by combining targeted alpha-particle therapy with Opdivo in Phase 1/2a trial, showing early positive safety signals.

#CATX Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

www.stocktitan.net/news/CATX/perspective-th...

#CatX #SpaceX

When Will Perspective Therapeutics Reveal Its Crucial 2024 Performance? Key Date Inside Comprehensive financial results and business highlights to be released post-market on March 26, showcasing full-year performance and strategic progress.

#CATX Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

www.stocktitan.net/news/CATX/perspective-th...

www.xcalable.org/product/kvm-...
Black Box DKM FX Transmitter Modular Interface Card
HDMI and USB over CATx – TAA Compliant TX MODULAR EXTENDER CARD @blackboxcomic.com #dkm #fx #transmitter #modular #interface #hdmi #usb #CATx #taa #tx @xcalable.bsky.social